1,432
Views
5
CrossRef citations to date
0
Altmetric
Brief Report

An electronic alert to decrease Kayexalate ordering

, , , , , & show all
Pages 1752-1754 | Received 17 Feb 2016, Accepted 18 Apr 2016, Published online: 17 May 2016
 

Abstract

Important safety concerns have recently emerged regarding the use of sodium polystyrene sulfonate (Kayexalate), a cation-exchange resin commonly used for the treatment of hyperkalemia. We implemented an electronic alert system at a tertiary care academic medical center to warn providers of the safety concerns of Kayexalate. We assessed the number of Kayexalate prescriptions per month, as well as the number of grams of Kayexalate ordered per month, one year before versus one year after implementing the alert. The mean (±SD) number of Kayexalate orders decreased from 123 (±12) to 76 (±14) orders/month (38% absolute reduction, p < 0.001) after implementing the alert. Additionally, the mean (±SD) amount of Kayexalate prescribed decreased from 3332 (±329) to 1885 (±358) g/month (43% absolute reduction, p < 0.001). We conclude that an electronic alert is an effective tool to decrease Kayexalate ordering.

Disclosure statement

G.D.S. reports having received a contract from MetaWare to study decision-support software. D.B.M. reports having consulted for ZS Pharma and for Up-to-date.

Funding

D.E.L. is supported by K23DK106448 from the National Institutes of Health-National Institute of Diabetes and Digestive and Kidney Diseases.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.